Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 529Neoplasms 475Carcinoma, Non-Small-Cell Lung 394Prostatic Neoplasms 308Colorectal Neoplasms 296Lung Neoplasms 259Neoplasm Metastasis 218Ovarian Neoplasms 200Leukemia, Myeloid, Acute 199Pancreatic Neoplasms 187Multiple Myeloma 175Squamous Cell Carcinoma of Head and Neck 134Recurrence 132Stomach Neoplasms 131Brain Neoplasms 126Carcinoma, Hepatocellular 125Melanoma 124Endometrial Neoplasms 122Glioblastoma 118Triple Negative Breast Neoplasms 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Hematologic Neoplasms 100Head and Neck Neoplasms 99Lymphoma 97Carcinoma, Renal Cell 97Urinary Bladder Neoplasms 93Sarcoma 90Glioma 88Lymphoma, Non-Hodgkin 82Rectal Neoplasms 81

Interventions

enzalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Hormone-sensitive Prostate Cancer × 90 days × Clear all
NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡